German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression of CD20 on leukemic cells the efficacy and tolerability of additional application of Rituximab together with chemotherapy is evaluated.
Adult Acute Lymphocytic Leukemia
DRUG: Cyclophosphamide|DRUG: Dexamethasone / Prednisolone|DRUG: Cytarabine|DRUG: Idarubicin|DRUG: Granulocyte-Colony-Stimulating Factor|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Rituximab|DRUG: HDARAC|DRUG: Vincristine|DRUG: Depocyte|DRUG: Asparaginase
Remission rate (cytologic, molecular), After induction; approximately 6 wks (exact time frame not specified)|Toxicity (CTC), After each cycle; time-frame not specified|Survival time, Duration of Remission, at 3 and 5 years
The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression of CD20 on leukemic cells the efficacy and tolerability of additional application of Rituximab together with chemotherapy is evaluated.